Smith & Nephew SNATS, Inc. (NYSE:SNN – Get Free Report) crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $30.96 and traded as low as $30.39. Smith & Nephew SNATS shares last traded at $30.4850, with a volume of 1,411,956 shares.
Analyst Upgrades and Downgrades
SNN has been the topic of a number of research analyst reports. Barclays lowered Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Sunday. Bank of America cut shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 8th. Zacks Research cut shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 5th. Finally, BTIG Research started coverage on shares of Smith & Nephew SNATS in a research report on Monday, August 31st. They set a “neutral” rating on the stock. One equities research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $31.91.
Check Out Our Latest Stock Report on Smith & Nephew SNATS
Smith & Nephew SNATS Stock Down 1.6%
The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. The business’s 50-day simple moving average is $28.92 and its 200-day simple moving average is $30.92.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Clearstead Trust LLC purchased a new stake in Smith & Nephew SNATS in the second quarter valued at $25,000. Ancora Advisors LLC raised its stake in shares of Smith & Nephew SNATS by 235.6% during the 3rd quarter. Ancora Advisors LLC now owns 970 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 681 shares during the last quarter. Addison Advisors LLC acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $43,000. Allworth Financial LP acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $48,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Smith & Nephew SNATS by 20.0% in the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 387 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.
About Smith & Nephew SNATS
Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.
See Also
- Five stocks we like better than Smith & Nephew SNATS
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
